Peng, Teng J.
Viscoli, Catherine
Khatri, Pooja
Wolfe, Stacey Q.
Bhatt, Nirav R.
Girotra, Tarun
Kamel, Hooman
Sheth, Kevin N. http://orcid.org/0000-0003-2003-5473
Article History
Accepted: 8 May 2022
First Online: 3 June 2022
Declarations
:
: No external funding was used in the preparation of this article.
: Dr. Peng, Dr. Viscoli, Dr. Wolfe, Dr. Bhatt, and Dr. Girotra have no relevant financial or nonfinancial interests to disclose. Dr. Khatri receives funding from Bayer for her effort as national leader of the PACIFIC-Stroke trial. Dr. Kamel serves as a primary investigator for the NIH-funded ARCADIA trial (NINDS U01NS095869), which receives in-kind study drug from the BMS-Pfizer Alliance for Eliquis<sup>®</sup> and ancillary study support from Roche Diagnostics; as Deputy Editor for <i>JAMA Neurology</i>; on clinical trial steering/executive committees for Medtronic, Janssen, and Javelin Medical; and on endpoint adjudication committees for NovoNordisk and Boehringer-Ingelheim. Dr. Sheth receives grant support from R01NS110721-01A1, U01NS106513, U24NS107215, U24NS107136, RO1NR018335, Bugher Center of Excellence in Hemorrhagic Stroke Research, American Heart Association/American Stroke Association, 2020AHA000BFCHS00199732, Biogen, Bard, and Hyperfine.
: TJP, CV, and KNS designed and conceptualized the study, performed the literature search, screened available data, and drafted the manuscript. SQW, PK, NRB, TG, and HK co-authored, edited, and critically reviewed the manuscript. All authors have read and approved the final manuscript for submission.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.